Mifepristone And Misoprostol Regimen

Continued support for misoprostol-only regimens for medication abortion and self-managed abortion between nine and 16 weeks gestation, the use of home pregnancy tests for follow-up care after a telehealth medication abortion, where adolescents and young adults go online to get abortion information, and disparities in recommended retesting for women with trichomonas vaginalis infections.

Perceived pain and sedation dosing during abortion procedures by demographics, PAPP-A as a novel screening for gestational age before medication abortion, patient experiences with progestin-only pills and attitudes towards OTC access.

A systemic review of “no-test” medication abortion, using an allis clamp during IUD placement, a trial of gabapentin for pain management during second-trimester abortions, and at-home urine pregnancy testing for follow-up of immediate management of an undesired pregnancy of unknown location.

Health care provider misconceptions about birth control as an abortifacient, a comprehension study of an over-the-counter combination birth control pill label, an updated Consensus from ACOG on menstrual suppression, and the effect of state-level abortion restrictions on early pregnancy loss management.

Trends in bHCG levels after medication abortion, a novel implant removal device, trends in IUD self-removal during the COVID-19 pandemic, and support for the patient-centeredness of telehealth birth control and abortion care.

Management of retained products of conception and a comparison of buccal and vaginal misoprostol for medication abortion, contraceptive values and preferences of adolescents and young adults, and more.

Benefits of increasing single-visit access to contraception, Black women’s experience with racism in reproductive health care in the U.S., the relationship between contraceptive satisfaction and sexual well-being, and more.

Pre-treatment with mifepristone for pain management in first-trimester surgical abortion care, high patient and provider satisfaction with telemedicine contraceptive counseling, an update to the CDC’s recommendation on self-administered DMPA-SC, and more.